{"id":92597,"date":"2026-01-08T13:35:54","date_gmt":"2026-01-08T12:35:54","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=92597"},"modified":"2026-01-08T13:36:58","modified_gmt":"2026-01-08T12:36:58","slug":"andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/","title":{"rendered":"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases"},"content":{"rendered":"<p><span class=\"Apple-converted-space\">\u00a0<\/span>Andera Partners, a leading European private equity player, today announced that it is co-leading a $159.8 million Series A round of Alveus Therapeutics, a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. The funding round was led by Andera Partners, New Rhein Healthcare Investors, and Omega Funds, with participation from Sanofi Capital, Kurma Partners, Avego BioScience Capital, and other healthcare investors.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Proceeds from the financing will support Phase 2 clinical development of ALV-100, the company\u2019s lead program, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>ALV-100 is a bifunctional fusion protein combining GIP receptor antagonism with GLP-1 receptor agonism, designed to deliver potent and sustained weight loss as well as long-term weight maintenance. Alveus\u2019 early-stage pipeline includes ALV-200, a highly selective amylin receptor 3 (AMYR3) peptide agonist, along with amylin-based small-molecule oral candidates and multifunctional biologic formats.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><i>\u201cObesity is one of the fastest-growing global healthcare challenges, and today\u2019s therapies leave patients struggling to maintain weight loss over time,\u201d <\/i>said <b>Raj Kannan, Chief Executive Officer of Alveus<\/b>. <i>\u201cALV-100 and our amylin-based pipeline are being developed to deliver durable efficacy with infrequent dosing, improved tolerability, and meaningfully better body-composition outcomes. With world-class investors and a team that has repeatedly brought metabolic medicines from concept to commercialization, Alveus is well positioned to lead the next wave of innovation in obesity therapeutics.\u201d<span class=\"Apple-converted-space\">\u00a0<\/span><\/i><\/p>\n<p><b>Jan Van den Bossche, Partner at Andera Partners, <\/b>added: <i>\u201cThis Series A financing underscores our confidence in Alveus\u2019 ability to set new standards of care in obesity and metabolic disease, which aligns with our mission to invest in innovation that makes a lasting difference in patients\u2019 lives. With preclinical and clinical operations anchored in the US and Denmark, Alveus combines global reach with executional excellence. We are proud to back a team that brings deep clinical insight and the ambition to make a meaningful impact on global health while scaling innovation worldwide.\u201d<span class=\"Apple-converted-space\">\u00a0<\/span><\/i><\/p>\n<p>In conjuction with the financing, Jan Van den Bossche has joined the Alveus Board of Directors.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Andera Partners, a leading European private equity player, today announced that it is co-leading a $159.8 million Series A round of Alveus Therapeutics, a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. The funding round was led by Andera Partners, New Rhein Healthcare Investors, and Omega Funds, with participation from Sanofi Capital,&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-92597","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"\u00a0Andera Partners, a leading European private equity player, today announced that it is co-leading a $159.8 million Series A round of Alveus Therapeutics, a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. The funding round was led by Andera Partners, New Rhein Healthcare Investors, and Omega Funds, with participation from Sanofi Capital,...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T12:35:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-08T12:36:58+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases\",\"datePublished\":\"2026-01-08T12:35:54+00:00\",\"dateModified\":\"2026-01-08T12:36:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/\"},\"wordCount\":357,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/\",\"name\":\"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2026-01-08T12:35:54+00:00\",\"dateModified\":\"2026-01-08T12:36:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases - ANDERA PARTNERS","og_description":"\u00a0Andera Partners, a leading European private equity player, today announced that it is co-leading a $159.8 million Series A round of Alveus Therapeutics, a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. The funding round was led by Andera Partners, New Rhein Healthcare Investors, and Omega Funds, with participation from Sanofi Capital,...","og_url":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2026-01-08T12:35:54+00:00","article_modified_time":"2026-01-08T12:36:58+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases","datePublished":"2026-01-08T12:35:54+00:00","dateModified":"2026-01-08T12:36:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/"},"wordCount":357,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/","url":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/","name":"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2026-01-08T12:35:54+00:00","dateModified":"2026-01-08T12:36:58+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-160-million-series-a-round-for-alveus-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=92597"}],"version-history":[{"count":3,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92597\/revisions"}],"predecessor-version":[{"id":92603,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92597\/revisions\/92603"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=92597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=92597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}